VIP-话题@MedSci

#VIP#

17篇内容 | 1195人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1746697, encodeId=b6571e466977f, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=英国MHRA已针对镥 (177Lu) vipivotide tetraxetan早期治疗前列腺癌发表了积极意见, objectType=article, longId=723941, objectId=864ae239414f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864ae239414f, replyNumber=0, likeNumber=90, createdTime=2022-07-17, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864ae239414f, moduleTitle=英国MHRA已针对镥 (177Lu) vipivotide tetraxetan早期治疗前列腺癌发表了积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864ae239414f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746696, encodeId=48cb1e4669655, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=Pemziviptadil治疗肺动脉高压，Ib / IIa期临床试验取得积极结果, objectType=article, longId=206365, objectId=faf120636599, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faf120636599, replyNumber=0, likeNumber=72, createdTime=2021-07-28, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faf120636599, moduleTitle=Pemziviptadil治疗肺动脉高压，Ib / IIa期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=faf120636599)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746691, encodeId=cec11e46691bb, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=印度监管机构：批准Favipiravir抗病毒片剂治疗COVID-19的临床试验, objectType=article, longId=193368, objectId=16431933689c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16431933689c, replyNumber=0, likeNumber=70, createdTime=2021-02-15, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16431933689c, moduleTitle=印度监管机构：批准Favipiravir抗病毒片剂治疗COVID-19的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16431933689c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746695, encodeId=fee51e4669535, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=RLF-100（aviptadil）可快速抑制新型冠状病毒的复制！, objectType=article, longId=198655, objectId=a827198655b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a827198655b2, replyNumber=0, likeNumber=73, createdTime=2021-07-01, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a827198655b2, moduleTitle=RLF-100（aviptadil）可快速抑制新型冠状病毒的复制！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a827198655b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746692, encodeId=7c8d1e4669213, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=血管活性肠多肽（VIP）RLF-100治疗COVID-19相关急性呼吸窘迫：患者已入组, objectType=article, longId=195151, objectId=50f71951518c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50f71951518c, replyNumber=0, likeNumber=70, createdTime=2021-01-06, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50f71951518c, moduleTitle=血管活性肠多肽（VIP）RLF-100治疗COVID-19相关急性呼吸窘迫：患者已入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50f71951518c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746694, encodeId=21071e46694bd, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=黑色素瘤癌症疫苗Seviprotimut-L，获得FDA快速通道认证, objectType=article, longId=196490, objectId=42171964903c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42171964903c, replyNumber=0, likeNumber=140, createdTime=2020-09-29, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42171964903c, moduleTitle=黑色素瘤癌症疫苗Seviprotimut-L，获得FDA快速通道认证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42171964903c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746693, encodeId=ee4e1e4669375, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=FDA授予RLF-100（Aviptadil）快速通道资格：治疗COVID-19呼吸窘迫, objectType=article, longId=196465, objectId=95f719646541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95f719646541, replyNumber=0, likeNumber=82, createdTime=2020-10-30, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95f719646541, moduleTitle=FDA授予RLF-100（Aviptadil）快速通道资格：治疗COVID-19呼吸窘迫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95f719646541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746689, encodeId=7a7d1e46689ea, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据, objectType=article, longId=182548, objectId=646d1825487e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=646d1825487e, replyNumber=0, likeNumber=74, createdTime=2020-03-16, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=646d1825487e, moduleTitle=2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=646d1825487e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746688, encodeId=99f71e4668839, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=辉瑞宣布镰状细胞病治疗药物rivipansel的后期研究未达到关键目标, objectType=article, longId=176953, objectId=30fd1e69539b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30fd1e69539b, replyNumber=0, likeNumber=85, createdTime=2019-09-14, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30fd1e69539b, moduleTitle=辉瑞宣布镰状细胞病治疗药物rivipansel的后期研究未达到关键目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30fd1e69539b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746690, encodeId=d3911e466905b, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant, objectType=article, longId=184902, objectId=8f0518490243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f0518490243, replyNumber=0, likeNumber=100, createdTime=2019-12-20, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f0518490243, moduleTitle=诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f0518490243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746687, encodeId=5d5d1e46687f2, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=Rivipansel治疗镰状细胞病的III期试验：未达到主要终点, objectType=article, longId=176941, objectId=47371e6941f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47371e6941f2, replyNumber=0, likeNumber=99, createdTime=2019-09-05, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47371e6941f2, moduleTitle=Rivipansel治疗镰状细胞病的III期试验：未达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47371e6941f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746685, encodeId=54d01e46685ed, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=Cell：人体生产保护性HIV抗体的VIP绿道, objectType=article, longId=150182, objectId=256a1501820a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=256a1501820a, replyNumber=0, likeNumber=91, createdTime=2019-08-24, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=256a1501820a, moduleTitle=Cell：人体生产保护性HIV抗体的VIP绿道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=256a1501820a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746686, encodeId=da0e1e46686c6, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=Curr HIV Res：药物不耐受转换为Eviplera®药物治疗后患者的表现, objectType=article, longId=162394, objectId=2e1b162394a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e1b162394a7, replyNumber=0, likeNumber=72, createdTime=2019-07-31, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e1b162394a7, moduleTitle=Curr HIV Res：药物不耐受转换为Eviplera®药物治疗后患者的表现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e1b162394a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746683, encodeId=cac51e4668367, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=Lancet Respir Med：前列腺素D2受体拮抗剂Fevipiprant，治疗中重度难治性哮喘, objectType=article, longId=77285, objectId=e129e728598, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e129e728598, replyNumber=0, likeNumber=87, createdTime=2017-01-18, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e129e728598, moduleTitle=Lancet Respir Med：前列腺素D2受体拮抗剂Fevipiprant，治疗中重度难治性哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e129e728598)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746684, encodeId=c4f41e46684a7, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=梅斯医学参加第15届世界内镜外科大会快来看看都有哪些VIP嘉宾？, objectType=article, longId=82199, objectId=8d6f8219943, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d6f8219943, replyNumber=0, likeNumber=80, createdTime=2017-05-01, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d6f8219943, moduleTitle=梅斯医学参加第15届世界内镜外科大会快来看看都有哪些VIP嘉宾？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d6f8219943)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746682, encodeId=10af1e4668260, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=选刊解惑，VIP专家在线等！精彩提问获免费选刊！, objectType=article, longId=64105, objectId=ae8a64105c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae8a64105c7, replyNumber=0, likeNumber=95, createdTime=2016-10-02, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae8a64105c7, moduleTitle=选刊解惑，VIP专家在线等！精彩提问获免费选刊！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae8a64105c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746681, encodeId=f6d51e46681b7, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, objectTitle=AJC：高残余血小板活性的ACS患者预后差(VIP研究), objectType=article, longId=21167, objectId=b9472116e4c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9472116e4c, replyNumber=0, likeNumber=64, createdTime=2013-10-03, rootId=0, userName=chendoc254, userId=933235833639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9472116e4c, moduleTitle=AJC：高残余血小板活性的ACS患者预后差(VIP研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9472116e4c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

VIP

2020-05-29

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

英国MHRA已针对镥 (177Lu) vipivotide tetraxetan早期治疗前列腺癌发表了积极意见

2022-07-17

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

Pemziviptadil治疗肺动脉高压，Ib / IIa期临床试验取得积极结果

2021-07-28

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

印度监管机构：批准Favipiravir抗病毒片剂治疗COVID-19的临床试验

2021-02-15

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

RLF-100（aviptadil）可快速抑制新型冠状病毒的复制！

2021-07-01

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

血管活性肠多肽（VIP）RLF-100治疗COVID-19相关急性呼吸窘迫：患者已入组

2021-01-06

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

黑色素瘤癌症疫苗Seviprotimut-L，获得FDA快速通道认证

2020-09-29

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

FDA授予RLF-100（Aviptadil）快速通道资格：治疗COVID-19呼吸窘迫

2020-10-30

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据

2020-03-16

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

辉瑞宣布镰状细胞病治疗药物rivipansel的后期研究未达到关键目标

2019-09-14

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant

2019-12-20

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

Rivipansel治疗镰状细胞病的III期试验：未达到主要终点

2019-09-05

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

Cell：人体生产保护性HIV抗体的VIP绿道

2019-08-24

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

Curr HIV Res：药物不耐受转换为Eviplera®药物治疗后患者的表现

2019-07-31

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

Lancet Respir Med：前列腺素D2受体拮抗剂Fevipiprant，治疗中重度难治性哮喘

2017-01-18

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

梅斯医学参加第15届世界内镜外科大会快来看看都有哪些VIP嘉宾？

2017-05-01

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

选刊解惑，VIP专家在线等！精彩提问获免费选刊！

2016-10-02

chendoc254 (审核中...)

前往app查看评论内容

#VIP#

AJC：高残余血小板活性的ACS患者预后差(VIP研究)

2013-10-03

科室
- - 订阅+
  - 更多科室
工具
服务